Idogen
  • Home
  • About Idogen
    • Idogen in brief
    • Management team
    • Board of directors and Auditor
    • Scientific advisory board
    • Business concept
    • Horizon 2020
    • Career
  • R&D
    • Idogen´s technology
    • Research overview
    • Project portfolio
    • Research collaborations
  • Investors
    • Stock information
    • Owners
    • Certified advisor
    • Analysts
    • Financial reports
    • Financial calendar
    • Upcoming events
    • Investors contact
  • Newsroom
    • Regulatory news
    • Non regulatory news
    • Financial reports
    • Presentations and Interviews
  • Contact us
  • Search
  • Menu Menu

Regulatory news

Nyheter - regulatoriska

7 April, 2021
BioStock interview with Åsa Schiött, Chief Scientific Officer at Idogen
30 March, 2021
BioStock interview with Rolf Ljung, scientific advisor to Idogen
25 February, 2021
The European Patent Office intends to grant Idogen’s patent application relevant to its cell therapy for hemophilia A
9 February, 2021
Idogen publishes Year-end report for 2020
23 October, 2020
Idogen AB Interim report January 1– September 30, 2020
15 September, 2020
Idogen provides update on timelines for the development of the tolerogenic cell therapy IDO 8
25 August, 2020
Idogen AB Interim report
18 June, 2020
Idogen’s cell therapy product successfully produced by GMP-certified manufacturing partner
4 June, 2020
Idogen’s first trading day on Nasdaq First North noted at Times Square in New York
2 June, 2020
Idogen has been approved for listing on Nasdaq First North Growth Market
20 May, 2020
Idogen will be listed on Nasdaq First North Growth Market on June 4, 2020
20 May, 2020
Idogen determines record date for consolidation of shares
12 May, 2020
Bulletin from the annual general meeting in Idogen AB on May 12, 2020
12 May, 2020
Idogen AB Interim report January 1 – March 31, 2020
1 April, 2020
Last day of trading with BTA in Idogen
31 March, 2020
Idogen receives MEUR 0.55 disbursement from Horizon 2020
30 March, 2020
Nomination Committee nominates cell therapy expert to Idogen AB’s Board of Directors
23 March, 2020
Idogen recruits a new Chief Medical Officer
18 March, 2020
Idogen publishes outcome in rights issue
28 February, 2020
Idogen publishes prospectus in connection with the forthcoming rights issue
17 February, 2020
Bulletin from the extraordinary general meeting in Idogen AB on February 17, 2020
7 February, 2020
Idogen presents at Biostock Live on February 13, 2020
5 February, 2020
Crown Princess and Prince Daniel visited Idogen
29 January, 2020
Idogen AB Year-end report 1 January-31 December 2019
28 January, 2020
Idogen AB (publ) announces rights issue of SEK 29 million
16 January, 2020
Idogen’s cell technology successfully advanced to large-scale production
13 December, 2019
Idogen files patent application for new tolerogenic cell therapy
13 November, 2019
Idogen signs collaboration agreement for the production of cell therapy in haemophilia
30 October, 2019
Idogen presents at Stora Aktiedagen in Gothenburg November 4th
22 October, 2019
Correction: Idogen AB Interim report January–September 2019
22 October, 2019
Idogen AB Interim report January–September 2019
23 September, 2019
Idogen’s investor events in October-November 2019
20 August, 2019
Interim report  1 January – 30 June 2019
15 July, 2019
Idogen appoints Anders Karlsson as new CEO
18 June, 2019
Idogen has successfully established a novel method for the company’s cell therapy
29 May, 2019
Idogen AB publishes Annual report for 2018
28 November, 2018
Idogen demonstrates proof-of-principle in a model of autoimmune disease
23 October, 2018
Interim report 1 January – 30 September 2018
18 October, 2018
Idogen’s investor events in October-November 2018
4 October, 2018
The Canadian Intellectual Property Office intends to grant Idogen’s patent application for tolerogenic cell therapy
26 September, 2018
Idogen’s IDO 8 granted orphan drug designation in the USA
21 August, 2018
Idogen AB Interim report January – June 2018
17 August, 2018
Idogen extends the project portfolio to projects in autoimmune diseases
25 April, 2018
Idogen appoints Hanne Risager Romedahl as new Chief Scientific Officer
24 April, 2018
Idogen AB Interim report January-March 2018
27 March, 2018
Idogen AB´s Annual report 2017 published
15 February, 2018
Year-end report 1 January – 31 December 2017
13 December, 2017
Idogen has been granted a patent in the USA for its immune therapy technology
13 September, 2017
BioStock publishes updated analysis of Idogen
21 June, 2017
Idogen participates in large Vinnova-initiative to make Sweden a leader in biological medicines
2 June, 2017
BioStock publishes analysis of Idogen
18 May, 2017
Idogen has been granted EUR 2.9 million funding from Horizon 2020
11 May, 2017
Tolerogenic vaccine for kidney transplantation to be next therapeutic area for Idogen
8 May, 2017
Nomination proposal strengthens Idogen’s Board within cell therapy and drug development
31 March, 2017
Idogen recruits Chief Medical Officer
23 March, 2017
European patent granted for Idogen’s vaccine technology
13 March, 2017
Idogen strengthens its position in the USA – important patent application receives Notice of Allowance
7 February, 2017
Idogen reaches formal granting of patent in Japan
16 January, 2017
Orphan drug designation formally granted for Idogen in Europe
13 January, 2017
The European Patent Office intends to grant Idogen’s patent application
12 December, 2016
Positive decision for Idogen’s orphan designation application in Europe
5 December, 2016
Japan Patent Office intends to grant Idogen’s patent application
30 November, 2016
Interview with Neil Thomas, Chief Business Officer in Idogen
21 November, 2016
Idogen signs agreement with global contract research partner
19 September, 2016
Idogen reports positive results for follow-up products in collaboration with the University of Oxford and strengthens the portfolio
12 September, 2016
Idogen reports important breakthrough – positive results from proof-of-concept study in human cells
8 July, 2016
Idogen initiates collaboration with the University of Oxford
8 July, 2016
Idogen reports positive pre-clinical results

Visit our news archive for older news

Subscribe to our news

Which information would you like to subscribe to?





Our press room at Cision

Idogen AB   |   Medicon Village   |   Scheelevägen 2   |   SE-223 81 Lund   |  Sweden   |  E-mail: info at idogen dot com

This project has received funding from the European Union’s Horizon 2020 research and innovation programme.

Scroll to top

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.

Read MoreAccept settings

Cookie and Privacy Settings



How we use cookies

We may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.

Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.

Essential Website Cookies

These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

Because these cookies are strictly necessary to deliver the website, refuseing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.

We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.

We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.

Other external services

We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.

Google Webfont Settings:

Google Map Settings:

Google reCaptcha Settings:

Vimeo and Youtube video embeds:

Privacy Policy

You can read about our cookies and privacy settings in detail on our Privacy Policy Page.

Privacy Policy ENG